Once weekly intraperitoneal administration of RMC-4627 as a single agent caused a dose-dependent reduction of leukemic burden in a xenograft model of human Ph+ B-ALL and enhanced the efficacy of the BCR-ABL tyrosine kinase inhibitor (TKI) dasatinib with acceptable in vivo tolerability. Here, ABL1 is linked to acute lymphoblastic leukemia.